NCT00362817View on ClinicalTrials.gov

Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

January 31, 2008

Study Completion Date

February 29, 2008

Conditions
Brain TumorBrain Metastases
Interventions
DRUG

carboplatin

IA carboplatin 200 mg/m2/day for each arterial injection on days 1 and 2.

DRUG

temozolomide

150 mg/m2/day orally Days 1-5. Treatment cycles to be repeated every 4 weeks.

Trial Locations (1)

43210

Ohio State University, Columbus

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT00362817 - Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases | Biotech Hunter | Biotech Hunter